CuraGen and TopoTarget's PXD101 Enters Phase I Solid Tumors Trial
Posted on: Friday, 11 August 2006, 12:00 CDT
Hot on the heels of beginning a similar trial in hematologic malignancies, CuraGen and TopoTarget have initiated a phase I clinical trial evaluating the administration of oral PXD101 in patients with advanced solid tumors.
The phase I study is an open-label, multi-center trial designed to establish the maximum tolerated dose (MTD) for oral PXD101 administered once or twice daily. Patients will be treated with oral PXD101 in a dose-escalation regimen and may continue to receive up to eight or more treatment cycles depending on disease response.
Primary objectives for the study include evaluation of the safety, tolerability and pharmacokinetics of oral PXD101. Secondary objectives include assessment of the pharmacokinetic profile of oral PXD101 administered once or twice daily at various dose levels and evaluation of anti-tumor activity.
The study is being conducted at sites both in the US and Europe, with preliminary results expected to be available by the end of 2007.
This news comes just days after the two companies announced the initiation of a phase I trial evaluating the safety and tolerability of PXD101 plus zacitidine in advanced hematologic malignancies.
The intravenous formulation of PXD101 is also being evaluated in a number of other indications, with phase II trials underway in multiple myeloma, T-cell lymphomas, and acute myelogenous leukemia.
Source: Datamonitor
Related Articles
- Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
- Targanta Therapeutics Releases Results From Phase 2 SIMPLIFI Study Evaluating Single or Infrequent Doses of Oritavancin
- Enanta Pharmaceuticals Initiates Phase Ia Study of Oral Antibiotic
- Transition Therapeutics Dose First Patient in Phase 2 Clinical Study of TT-223 in Type 2 Diabetes
- ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
- Elan and Transition Therapeutics Dose First Patient in Phase 2 Clinical Study of ELND005 (AZD-103) in Alzheimer's Disease
- Knopp Neurosciences Presents Results of Phase 1 Ascending Single-Dose Study of KNS-760704
- BioSante Pharmaceuticals Announces Oral Contraceptive Phase II Study Initiation
- Predix Pharmaceuticals Announces Initiation of Phase Ib Clinical Trial in Alzheimer's Patients; Provides Initial Dose Study Update
- FibroGen Reports Phase 1 Results of Investigational Oral Anemia Therapy, FG-2216, and New Data From Phase 2A Study in Anemic Chronic Kidney Disease Patients
 |
 |
User Comments (0)
RSS Feeds